Sagimet Biosciences Inc. (SGMT)
| Market Cap | 193.83M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -57.67M |
| Shares Out | 32.52M |
| EPS (ttm) | -1.79 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 239,890 |
| Open | 6.05 |
| Previous Close | 6.06 |
| Day's Range | 5.87 - 6.05 |
| 52-Week Range | 1.73 - 11.41 |
| Beta | 3.37 |
| Analysts | Strong Buy |
| Price Target | 29.71 (+398.49%) |
| Earnings Date | Nov 13, 2025 |
About SGMT
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs, such as various solid tumor an... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for SGMT stock is "Strong Buy." The 12-month stock price target is $29.71, which is an increase of 398.49% from the latest price.
News
Sagimet: Positive Denifanstat Combination PK Data Could Lead To Untapped Market
Sagimet Biosciences Inc. remains a Strong Buy, driven by positive PK Denifanstat + Resmetirom combination data and advancing clinical programs in acne and MASH. SGMT's denifanstat plus resmetirom comb...
Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination
The combination of denifanstat and resmetirom was generally well-tolerated Pharmacokinetic (PK) results support further development of the combination A Phase 2 trial of a denifanstat/resmetirom combi...
Sagimet's License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China's National Medical Products Administration
SAN MATEO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...
Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment
-Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a randomized, d...
Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN MATEO, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...
Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference
SAN MATEO, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...
Sagimet Biosciences Advances Denifanstat: Q3 Earnings And Upcoming Catalysts
Sagimet Biosciences reported a Q3 GAAP EPS loss of -$0.40, missing estimates, but maintains strong momentum with Denifanstat's clinical progress. SGMT's cash position remains robust at $125.5 million,...
Sagimet Biosciences Presents Two Denifanstat Posters at AASLD—The Liver Meeting® 2025
A secondary analysis of FASCINATE-2 Phase 2 trial demonstrated denifanstat improved fibrosis, inflammation and steatosis in advanced qF4 MASH patients as measured by artificial intelligence (AI) digit...
Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference
Denifanstat met all primary and secondary endpoints versus placebo and was generally well tolerated in a Phase 3 clinical trial in acne in China conducted by license partner Ascletis Ascletis announce...
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
SAN MATEO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional ...
Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration
- Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a Phase III ra...
Denifanstat Advances: Sagimet Builds Momentum Toward 2026 Readouts
Sagimet Biosciences (SGMT) is well-positioned financially, with $135 million in cash and minimal debt, supporting operations through early 2028. SGMT's lead asset, denifanstat, is advancing in combina...
Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025
SAN MATEO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...
Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis
Denifanstat met all primary and secondary endpoints versus placebo Denifanstat was generally well tolerated Sagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor, TVB-3567...
Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit
SAN MATEO, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional...
Sagimet Biosciences Inc. (SGMT) Presents At Cantor Global Healthcare Conference 2025 Transcript
Sagimet Biosciences Inc. (NASDAQ:SGMT) Cantor Global Healthcare Conference 2025 September 3, 2025 1:35 PM EDT Company Participants David Happel - CEO, President & Director Eduardo Martins - Chief Med...
Sagimet Gains Momentum As FDA Eases Path For MASH Drug Development
Sagimet Biosciences offers a unique play in MASH with Denifanstat, a FASN inhibitor showing both fat reduction and fibrosis regression in Phase 2b. The FDA's acceptance of non-invasive trial endpoints...
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
SAN MATEO, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...
Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Denifanstat met all primary and secondary endpoints in Phase 3 clinical trial in moderate to severe acne conducted by license partner Ascletis in China
Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference
SAN MATEO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...
Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025
SAN MATEO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...
Sagimet: Positive China Partner Acne Vulgaris Data Bodes Well For TVB-3567
Sagimet Biosciences' partner Ascletis reported strong phase 3 results for denifanstat in moderate-to-severe acne, validating FASN inhibition as a novel oral treatment. Sagimet is advancing next-gen FA...
Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis
Denifanstat met all primary and secondary endpoints versus placebo Denifanstat was well tolerated Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to seve...
Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025
SAN MATEO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic ...
Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Phase 1 clinical trial to evaluate the pharmacokinetics (PK) of a combination of denifanstat and resmetirom expected to initiate in 2H 2025; data readout expected 1H 2026 Phase 1 clinical trial to eva...